Resverlogix Corp.

Events/Webcasts

Webcasts & Presentations

Periocically Resverlogix will webcast from selected conferences/events. Active links will be posted here.

June 13, 2016: Resverlogix Quarterly Update:  PDF Presentation Link to webcast: http://services.choruscall.ca/links/resverlogix20160613.html

June 7, 2016: Bio International 2016 - Corporate Update. We invite interested parties to visit here: http://www.veracast.com/webcasts/bio/internationalconvention2016/37214271955.cfm

On Sept. 25, 2015, Resverlogix’s clinical and scientific teams along with Professor Kausik K. Ray and Dr. Kamyar Kalantar-Zadeh of the BETonMACE clinical steering committee presented a Research & Development Update for apabetalone (RVX-208) in New York City. The archived event can be accessed here: http://services.choruscall.ca/links/resverlogix150929.html

Events - Q3 2016

Resverlogix will be attending several key industry conferences. Website will be udated as presentation opportunities become available. Please note: not all events offer a presentation opportunity and this list is subject to change.

Aug. 27-31, 2016: ESC Congress 2016

Sept. 11-13, 2016: Rodman & Renshaw 18th Annual Global Investment Conference

Sept. 12-16, 2016: EASD 2016 

Sept. 13-15, 2016: BioPharm America

Resverlogix in the Media

March 29: CTV news filmed on location the RVX lab featuring the Sanofi Biogenius competition

Jan. 20, 2016: Resverlogix featured in the Life Sciences Report

Sept. 2015: At the 2015 Rodman & Renshaw healthcase conference, Don McCaffrey had a video interview with Stock News Now (SNN).

Aug. 26, 2015: Resverlogix featured in the Life Sciences Report: Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey

June 25, 2015: Resverlogix’s Dr. Ewelina Kulikowski has written and published an article for the summer 2015 issue of the European Biopharmaceutical Review (EBR) titled, “New Direction.”

April 22, 2015: Donald McCaffrey, President & CEO on BNN’s Business Day
 

April 27, 2015- BioCentury: Hepalink gains rights to Resverlogix’s RVX-208 in China

April 28, 2015- BioWorld Today: Phase III Starting Soon. Resverlogix getting specific: With potential $400M BET, Hepalink licensing accord, by Randy Osborne. 

April 28, 2015- Bloomberg Business: Resverlogix in Discussions to Be Bought, by Eric Lam.

April 28, 2015- BioSpace Breaking News: Resverlogix (RVX.TO) CEO Says It’s in Talks With Suitors, After $100M in Q1 Deals, by Riley McDermid. 

April 28, 2015- Fierce Biotech: Resverlogix gets a $116M China Drug development deal, stokes buyout buzz, by John Carroll. 

April 28, 2015 - GEN News Highlights: Hepalink Buys China-Area Rights to Resverlogix's CV Candidate for Up-to-$441.5M.

To arrange a media interview, please contact Sarah Zapotichny, Director of Investor Relations & Corporate Communications at sarah@resverlogix.com.